Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022-2024 Period.
- DOI
- 10.3390/vaccines14090790
- Published
- 2026 Sep 9
- Container
- Vaccines
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/vaccines14090790,
title = {Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022-2024 Period.},
author = {Read SH and Kutikova L and Gusto G and Kapnang R and Quignot N and Khachatryan A and El Guerche-Séblain C and Petit V and Fix J and Rousculp MD and Janssen C and Launay O},
year = {2026},
journal = {Vaccines},
doi = {10.3390/vaccines14090790},
url = {https://doi.org/10.3390/vaccines14090790}
}RIS
TY - JOUR TI - Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022-2024 Period. AU - Read SH AU - Kutikova L AU - Gusto G AU - Kapnang R AU - Quignot N AU - Khachatryan A AU - El Guerche-Séblain C AU - Petit V AU - Fix J AU - Rousculp MD AU - Janssen C AU - Launay O PY - 2026 JO - Vaccines DO - 10.3390/vaccines14090790 UR - https://doi.org/10.3390/vaccines14090790 ER -
APA
SH, R., L, K., G, G., R, K., N, Q., A, K., C, E. G., V, P., J, F., MD, R., C, J., & O, L. (2026). Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022-2024 Period.. Vaccines. https://doi.org/10.3390/vaccines14090790
Source records
- pubmed · retrieved 2026-09-26T17:35:02.518Z